Interstitial lung disease

28 clinical trials

Quick filters

Clinical trials for Interstitial lung disease

28 trials across Europe

See all trials →

Quick filters

28 Clinical trials

Systemic scleroderma+1

Recruiting

Investigational

Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Amlitelimab
Sponsor:Scleroderma Research Foundation

Contact Research Centre

Interstitial lung disease+1

Recruiting

InvestigationalNo placebo

Assessing Hemodynamic Effect and Safety of TX000045 in Adults with Pulmonary Hypertension Secondary to Interstitial Lung Disease

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:TX000045

Contact Research Centre

Interstitial lung disease

Recruiting

Investigational

Safety, Pharmacokinetics, and Exploratory Efficacy of BI 1015550 and Nerandomilast in Children and Adolescents Aged 2‑17 Years With Fibrosing Interstitial Lung Disease

Investigational

Belgium

Participants:0–17 years
Substances:Bi 1015550
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Interstitial lung disease+1

Recruiting

Investigational

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Treprostinil
Sponsor:Liquidia Technologies Inc.

Contact Research Centre

Systemic scleroderma+5

Recruiting

InvestigationalNo placebo

Using 68Ga-FAPI-46 imaging to detect fibrosis in patients with inflammatory diseases such as Crohn's disease, ulcerative colitis, systemic sclerosis, and lung fibrosis.

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Interstitial lung disease+1

Recruiting

Investigational

A study to evaluate the effectiveness of BI 1015550 in people with lung abnormalities and a family history of pulmonary fibrosis

Investigational

Belgium

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Bi 1015550
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

See all trials →

Interstitial lung disease

Clinical trials for Interstitial lung disease

Systemic scleroderma+1

Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma

Interstitial lung disease+1

Assessing Hemodynamic Effect and Safety of TX000045 in Adults with Pulmonary Hypertension Secondary to Interstitial Lung Disease

Interstitial lung disease

Safety, Pharmacokinetics, and Exploratory Efficacy of BI 1015550 and Nerandomilast in Children and Adolescents Aged 2‑17 Years With Fibrosing Interstitial Lung Disease

Interstitial lung disease+1

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Systemic scleroderma+5

Using 68Ga-FAPI-46 imaging to detect fibrosis in patients with inflammatory diseases such as Crohn's disease, ulcerative colitis, systemic sclerosis, and lung fibrosis.

Interstitial lung disease+1

A study to evaluate the effectiveness of BI 1015550 in people with lung abnormalities and a family history of pulmonary fibrosis

Filter the trials

Prefer not to search? Our Concierge searches the trials for you.